AZ Confident New Cancer Drugs Can Drive Return To Sales Growth
Executive Summary
The drugs major is looking to return to sales growth in 2018 and believes that its oncology division will be the main driver as the last wave of patent expiries ebbs away.
You may also be interested in...
AstraZeneca's Pipeline Reaps Rewards Of Return To Science
AstraZeneca rounded off a busy 2017 full of R&D highs, but some huge lows, with a full Phase III pipeline that it says shows how far the company has come since Pascal Soriot took the reins in 2012 and spearheaded a renewed focus on science. But will the company become a victim of its own success?
AstraZeneca's Calquence Steps Into Blood Cancer Ring With Mighty Imbruvica
AstraZeneca's launch of BTK inhibitor Calquence (acalabrutinib) in mantle cell lymphoma will mark the company's market entry in liquid tumors, up against a formidable competitor – J&J/Abbvie's first-in-class Imbruvica.
AstraZeneca Says 'IDO' To Incyte For Imfinzi Marriage
As the major immuno-oncology players seek out the best combination therapies, AstraZeneca and Incyte are starting a Phase III trial evaluating Imfinzi and the IDO inhibitor epacadostat in Stage III NSCLC.